Interactions between nexium-i-v(esomeprazole) and Etravirine (etravirine)
esomeprazole and etravirine (Moderate Drug-Drug)
MONITOR: Coadministration of etravirine with a drug that is both a substrate as well as inhibitor of CYP450 2C19 and/or 2C9 may result in increased plasma concentrations of both drugs. Etravirine itself is also a substrate and inhibitor of CYP450 2C19 and 2C9. Theoretically, metabolism of etravirine and the coadministered drug may be mutually inhibited when used in combination. In 18 study subjects administered etravirine with the CYP450 2C19 inhibitor omeprazole (40 mg once a day), etravirine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 17% and 41%, respectively. The effect of etravirine on omeprazole pharmacokinetics was not reported.
MANAGEMENT: Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a CYP450 2C19 or 2C9 inhibitor. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 2C19 or 2C9.
